NASDAQ:SGEN - Seattle Genetics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$65.11 -0.38 (-0.58 %)
(As of 06/17/2018 04:00 PM ET)
Previous Close$65.11
Today's Range$65.02 - $66.79
52-Week Range$45.31 - $69.71
Volume2.04 million shs
Average Volume845,060 shs
Market Capitalization$10.30 billion
P/E Ratio-73.99
Dividend YieldN/A
Beta1.91

About Seattle Genetics (NASDAQ:SGEN)

Seattle Genetics logoSeattle Genetics, Inc., a biotechnology company, focuses on the development and commercialization of targeted therapies for the treatment of cancer worldwide. It markets ADCETRIS, an antibody-drug conjugate for the treatment of relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma. The company also develops enfortumab vedotin, which is in Phase 1 clinical trial for Nectin-4-positive solid tumors, including bladder cancer; and tisotumab vedotin that is in Phase II clinical trial for patients with cervical cancer and solid tumors. In addition, it conducts phase 3 clinical trials of ADCETRIS which includes ECHELON-1 for patients with newly diagnosed advanced stage classical Hodgkin lymphoma; ECHELON-2 for patients with newly diagnosed CD30-expressing MTCL; and the CHECKMATE 812 for patients with relapsed or refractory or transplant-ineligible, and advanced classical Hodgkin lymphoma. Further, the company's earlier stage clinical pipeline includes six other ADC programs consisting of ladiratuzumab vedotin, denintuzumab mafodotin, SGN-CD19B, SGN-CD123A, SGN-CD33A, and SGN-CD352A, as well as two immuno-oncology agents, including SEA-CD40 and SGN-2FF. It has collaborations for its ADC technology with various biotechnology and pharmaceutical companies, including AbbVie Biotechnology Ltd.; Bayer Pharma AG; Celldex Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline LLC; Pfizer, Inc., PSMA Development Company LLC; Takeda Pharmaceutical Company Limited, Unum Therapeutics, Inc., and Genmab A/S, as well as has co-development agreement with Agensys, Inc. Seattle Genetics, Inc. was founded in 1998 and is headquartered in Bothell, Washington.

Receive SGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for SGEN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:SGEN
CUSIP81257810
Phone425-527-4000

Debt

Debt-to-Equity RatioN/A
Current Ratio3.78
Quick Ratio3.35

Price-To-Earnings

Trailing P/E Ratio-73.99
Forward P/E Ratio-38.76
P/E GrowthN/A

Sales & Book Value

Annual Sales$482.25 million
Price / Sales21.36
Cash FlowN/A
Price / CashN/A
Book Value$4.71 per share
Price / Book13.82

Profitability

EPS (Most Recent Fiscal Year)($0.88)
Net Income$-125,530,000.00
Net Margins-34.51%
Return on Equity-29.74%
Return on Assets-23.94%

Miscellaneous

Employees1,100
Outstanding Shares158,220,000

Seattle Genetics (NASDAQ:SGEN) Frequently Asked Questions

What is Seattle Genetics' stock symbol?

Seattle Genetics trades on the NASDAQ under the ticker symbol "SGEN."

How were Seattle Genetics' earnings last quarter?

Seattle Genetics, Inc. (NASDAQ:SGEN) posted its quarterly earnings data on Thursday, April, 26th. The biotechnology company reported ($0.73) earnings per share for the quarter, missing the consensus estimate of ($0.42) by $0.31. The biotechnology company had revenue of $140.59 million for the quarter, compared to analysts' expectations of $119.04 million. Seattle Genetics had a negative return on equity of 29.74% and a negative net margin of 34.51%. The company's revenue for the quarter was up 28.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.42) earnings per share. View Seattle Genetics' Earnings History.

When is Seattle Genetics' next earnings date?

Seattle Genetics is scheduled to release their next quarterly earnings announcement on Wednesday, July, 25th 2018. View Earnings Estimates for Seattle Genetics.

What price target have analysts set for SGEN?

17 brokerages have issued 12-month price objectives for Seattle Genetics' shares. Their predictions range from $48.00 to $80.00. On average, they anticipate Seattle Genetics' stock price to reach $65.1429 in the next year. View Analyst Ratings for Seattle Genetics.

What are Wall Street analysts saying about Seattle Genetics stock?

Here are some recent quotes from research analysts about Seattle Genetics stock:
  • 1. HC Wainwright analysts commented, "We believe the FDA warning against CPI usage in the first-line setting last month, and the long DOR by CPI treatment in the second-line setting presented at ASCO this weekend, may result in a delay in EV-201 trial enrollment and primary study completion initially planned in 2020. Last month, the FDA issued a warning against single-agent checkpoint inhibition for frontline PDL1-low patients, based on a recent data monitoring committee (DMC) assessment for the phase 3 KEYNOTE-361 study (pembrolizumab, Merck, MRK; not rated) and the phase 3 IMvigor130 study (atezolizumab, Genentech, DNA; not rated) results." (6/5/2018)
  • 2. Cann analysts commented, "We have not included any sales or earnings from enfortumab vedotin by 2022 due to its stage of development, but we are encouraged by its development program, including data in the ASCO abstract and its having received Breakthrough Therapy Designation. Genetics’ approved drug for Hodgkin’s lymphoma, had sales of $307.6 million, or 63.8% of total revenue, in 2017. We estimate that Adcetris sales, including additional indications, CTCL and Anaplastic large cell lymphoma, and label expansion into frontline Hodgkin’s lymphoma, will increase to $766.7 million in 2022 and account for 70% of revenue. Continued strong data from ECHELON-1 are expected to drive adoption in the frontline Hodgkin’s setting." (5/17/2018)
  • 3. According to Zacks Investment Research, "Seattle Genetics' dependence on one product – Adcetris– for growth has its inherent risks. The recent label expansion of Merck’s Keytruda in the lymphoma indication is likely to increase competition. Though the company has multiple candidates in its pipeline, most of them are in early stages of development. However, efforts to expand Adcetris’s label is encouraging. The label expansion in pcALCL, CD30-expressing MF and T-cell lymphoma will boost sales. The company’s collaboration with Takeda for the global development and commercialization of Adcetris is encouraging. Meanwhile, the company’s shares have underperformed the industry in the past year. Estimates movement remains mixed ahead of Q1 results. Seattle Genetics has a mixed record of earnings surprises in the recent quarters." (4/23/2018)
  • 4. JPMorgan Chase & Co. analysts commented, "Forecasts; We Expect Shares to Be Pressured Monday morning, ViewRay announced preliminary 2017 revenue of $34M and 4Q17 orders of $34M. Both metrics were significantly below our expectations. With so much investor focus on system sales and conversion to revenue, we expect VRAY to trade off today.   The company recognized revenue on 4 MRIdian Linac Systems in the quarter. For the full year, VRAY announced total revenue of $34M. We had modeled $42.5M in revenue for the full year. Management noted that revenue recognition was delayed on one of the 5 systems shipped or installed in the quarter. That delay should result in $7M in revenue recognized in a later period. Investors have been eager to see backlog convert to revenue and this miss is likely to disappoint.   In the quarter, VRAY received $34M in new MRIdian Linac System orders, less than the $48M we had forecasted. That order number is lower the company’s orders in the second quarter and likely does not demonstrate enough of an uptick in momentum from the $29.9M order reported in 3Q." (1/9/2018)

Who are some of Seattle Genetics' key competitors?

Who are Seattle Genetics' key executives?

Seattle Genetics' management team includes the folowing people:
  • Dr. Clay B. Siegall, Co-Founder, Chairman, Pres & CEO (Age 57)
  • Mr. Todd E. Simpson, Chief Financial Officer (Age 57)
  • Dr. Vaughn B. Himes, Chief Technology Officer (Age 57)
  • Ms. Jean I. Liu, Gen. Counsel, Exec. VP of Legal Affairs & Corp. Sec. (Age 50)
  • Dr. Jonathan G. Drachman, Strategic Advisor for Innovation (Age 56)

Has Seattle Genetics been receiving favorable news coverage?

News stories about SGEN stock have trended somewhat positive this week, according to Accern Sentiment. The research group rates the sentiment of press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Seattle Genetics earned a daily sentiment score of 0.10 on Accern's scale. They also assigned headlines about the biotechnology company an impact score of 46.34 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

Who are Seattle Genetics' major shareholders?

Seattle Genetics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BAKER BROS. ADVISORS LP (32.10%), Baillie Gifford & Co. (9.27%), BlackRock Inc. (5.37%), Manning & Napier Group LLC (1.48%), Wasatch Advisors Inc. (0.62%) and Pinnacle Associates Ltd. (0.57%). Company insiders that own Seattle Genetics stock include Bros Advisors Lp Baker, Clay B Siegall, Darren S Cline, Eric Dobmeier, Felix Baker, Jonathan G Drachman, Marc E Lippman, Todd E Simpson and Vaughn B Himes. View Institutional Ownership Trends for Seattle Genetics.

Which institutional investors are selling Seattle Genetics stock?

SGEN stock was sold by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., Legal & General Group Plc, Manning & Napier Group LLC, Pinnacle Associates Ltd., Russell Investments Group Ltd., Swiss National Bank, Opus Point Partners Management LLC and Great West Life Assurance Co. Can. Company insiders that have sold Seattle Genetics company stock in the last year include Clay B Siegall, Darren S Cline, Eric Dobmeier, Jonathan G Drachman, Marc E Lippman, Todd E Simpson and Vaughn B Himes. View Insider Buying and Selling for Seattle Genetics.

Which institutional investors are buying Seattle Genetics stock?

SGEN stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Nexthera Capital LP, Wells Fargo & Company MN, UBS Group AG, Bedell Frazier Investment Counseling LLC, Summit Trail Advisors LLC, JPMorgan Chase & Co. and Millennium Management LLC. Company insiders that have bought Seattle Genetics stock in the last two years include Bros Advisors Lp Baker and Felix Baker. View Insider Buying and Selling for Seattle Genetics.

How do I buy shares of Seattle Genetics?

Shares of SGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Seattle Genetics' stock price today?

One share of SGEN stock can currently be purchased for approximately $65.11.

How big of a company is Seattle Genetics?

Seattle Genetics has a market capitalization of $10.30 billion and generates $482.25 million in revenue each year. The biotechnology company earns $-125,530,000.00 in net income (profit) each year or ($0.88) on an earnings per share basis. Seattle Genetics employs 1,100 workers across the globe.

How can I contact Seattle Genetics?

Seattle Genetics' mailing address is 21823 30TH DRIVE SE SUITE, BOTHELL WA, 98021. The biotechnology company can be reached via phone at 425-527-4000 or via email at [email protected]


MarketBeat Community Rating for Seattle Genetics (SGEN)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  410 (Vote Outperform)
Underperform Votes:  452 (Vote Underperform)
Total Votes:  862
MarketBeat's community ratings are surveys of what our community members think about Seattle Genetics and other stocks. Vote "Outperform" if you believe SGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Seattle Genetics (NASDAQ:SGEN) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
17 Wall Street analysts have issued ratings and price targets for Seattle Genetics in the last 12 months. Their average twelve-month price target is $65.1429, suggesting that the stock has a possible upside of 0.05%. The high price target for SGEN is $80.00 and the low price target for SGEN is $48.00. There are currently 7 hold ratings and 10 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyHold
Consensus Rating Score: 2.592.532.562.38
Ratings Breakdown: 0 Sell Rating(s)
7 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
8 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
8 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
11 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $65.1429$63.7143$64.00$63.20
Price Target Upside: 0.05% upside8.91% upside7.89% upside16.69% upside

Seattle Genetics (NASDAQ:SGEN) Consensus Price Target History

Price Target History for Seattle Genetics (NASDAQ:SGEN)

Seattle Genetics (NASDAQ:SGEN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/11/2018SunTrust BanksUpgradeHold ➝ Buy$60.00 ➝ $80.00MediumView Rating Details
6/5/2018HC WainwrightReiterated RatingBuyMediumView Rating Details
5/17/2018CannReiterated RatingHoldMediumView Rating Details
4/26/2018Cantor FitzgeraldSet Price TargetHold$50.00HighView Rating Details
3/21/2018Morgan StanleyLower Price TargetOverweight ➝ Overweight$69.00 ➝ $67.00LowView Rating Details
3/20/2018Royal Bank of CanadaReiterated RatingBuy$73.00MediumView Rating Details
3/20/2018BarclaysInitiated CoverageOverweight ➝ Overweight$74.00HighView Rating Details
3/13/2018CowenReiterated RatingHoldLowView Rating Details
2/14/2018JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$60.00LowView Rating Details
2/7/2018Bank of AmericaLower Price TargetNeutral ➝ Neutral$70.00 ➝ $68.00LowView Rating Details
2/7/2018Needham & Company LLCReiterated RatingBuy ➝ Buy$72.00 ➝ $74.00HighView Rating Details
1/2/2018OppenheimerReiterated RatingHoldHighView Rating Details
10/26/2017Jefferies Financial GroupReiterated RatingBuy$53.00N/AView Rating Details
10/23/2017GuggenheimReiterated RatingBuy ➝ Buy$72.00N/AView Rating Details
10/6/2017Goldman Sachs GroupReiterated RatingNeutral ➝ Neutral$64.00N/AView Rating Details
6/27/2017Piper Jaffray CompaniesReiterated RatingNeutral$48.00HighView Rating Details
6/26/2017William BlairReiterated RatingOutperformHighView Rating Details
4/7/2017Leerink SwannBoost Price TargetOutperform$70.00 ➝ $74.00MediumView Rating Details
3/16/2017CIBCInitiated CoverageMarket Perform ➝ Market PerformLowView Rating Details
2/13/2017Credit Suisse GroupBoost Price TargetNeutral$62.00 ➝ $66.00N/AView Rating Details
1/5/2017Maxim GroupReiterated RatingReduceN/AView Rating Details
(Data available from 6/17/2016 forward)

Earnings

Seattle Genetics (NASDAQ:SGEN) Earnings History and Estimates Chart

Earnings by Quarter for Seattle Genetics (NASDAQ:SGEN)

Seattle Genetics (NASDAQ:SGEN) Earnings Estimates

2018 EPS Consensus Estimate: ($1.60)
2019 EPS Consensus Estimate: ($0.73)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20184($0.49)($0.41)($0.45)
Q2 20184($0.50)($0.38)($0.43)
Q3 20184($0.49)($0.30)($0.36)
Q4 20184($0.47)($0.26)($0.36)
Q1 20191($0.31)($0.31)($0.31)
Q2 20191($0.21)($0.21)($0.21)
Q3 20191($0.14)($0.14)($0.14)
Q4 20191($0.07)($0.07)($0.07)

Seattle Genetics (NASDAQ SGEN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/25/2018($0.40)N/AView Earnings Details
4/26/2018Q1 2018($0.42)($0.73)$119.04 million$140.59 millionViewN/AView Earnings Details
2/6/2018Q4 2017($0.43)($0.41)$123.99 million$129.61 millionViewListenView Earnings Details
10/26/2017Q3 2017($0.42)($0.19)$112.76 million$135.29 millionViewN/AView Earnings Details
7/27/2017Q2 2017($0.42)($0.39)$105.92 million$108.20 millionViewN/AView Earnings Details
4/27/2017Q1 2017($0.41)($0.42)$103.23 million$109.10 millionViewN/AView Earnings Details
2/9/2017Q416($0.34)($0.39)$106.49 million$105.30 millionViewListenView Earnings Details
10/27/2016Q316($0.29)($0.23)$4.34 million$106.30 millionViewListenView Earnings Details
7/26/2016Q216($0.32)($0.23)$94.56 million$95.40 millionViewListenView Earnings Details
4/28/2016Q116($0.09)($0.15)$116.49 million$111.15 millionViewListenView Earnings Details
2/9/2016Q415($0.20)($0.18)$88.00 million$93.50 millionViewN/AView Earnings Details
10/29/2015Q315($0.20)($0.21)$82.35 million$84.10 millionViewListenView Earnings Details
7/30/2015Q215($0.26)($0.38)$78.21 million$77.10 millionViewListenView Earnings Details
4/30/2015Q1($0.19)($0.17)$74.57 million$82.20 millionViewListenView Earnings Details
2/10/2015Q414($0.25)($0.22)$68.34 million$74.30 millionViewListenView Earnings Details
10/30/2014Q314($0.24)($0.13)$66.90 million$75.80 millionViewListenView Earnings Details
7/31/2014Q214($0.23)($0.14)$65.04 million$68.30 millionViewListenView Earnings Details
5/1/2014Q114($0.21)($0.13)$64.62 million$68.30 millionViewListenView Earnings Details
2/11/2014Q413($0.24)($0.13)$59.50 million$67.40 millionViewListenView Earnings Details
11/5/2013Q313($0.22)($0.19)$57.79 million$71.00 millionViewListenView Earnings Details
7/31/2013Q2 2013($0.20)($0.06)$58.12 million$773.60 millionViewListenView Earnings Details
5/7/2013Q1 2013($0.19)($0.14)$53.72 million$57.32 millionViewListenView Earnings Details
2/12/2013Q4 2012($0.10)($0.09)$57.21 million$63.90 millionViewListenView Earnings Details
11/7/2012Q312($0.14)($0.12)$52.79 million$49.83 millionViewN/AView Earnings Details
8/8/2012($0.15)($0.15)ViewN/AView Earnings Details
5/8/2012($0.11)($0.11)ViewN/AView Earnings Details
2/13/2012($0.31)($0.24)ViewN/AView Earnings Details
11/3/2011($0.46)($0.35)ViewN/AView Earnings Details
8/4/2011Q2 2011($0.39)($0.45)ViewN/AView Earnings Details
5/5/2011Q1 2011($0.36)($0.30)ViewN/AView Earnings Details
2/8/2011Q4 2010($0.38)($0.34)ViewN/AView Earnings Details
11/1/2010Q3 2010($0.35)($0.34)ViewN/AView Earnings Details
7/27/2010Q2 2010($0.01)($0.08)ViewN/AView Earnings Details
4/27/2010Q1 2010$0.04$0.11ViewN/AView Earnings Details
2/9/2010Q4 2009($0.23)($0.12)ViewN/AView Earnings Details
10/22/2009Q3 2009($0.26)($0.21)ViewN/AView Earnings Details
7/23/2009Q2 2009($0.29)($0.26)ViewN/AView Earnings Details
4/23/2009Q1 2009($0.28)($0.33)ViewN/AView Earnings Details
2/5/2009Q4 2008($0.30)($0.38)ViewN/AView Earnings Details
10/23/2008Q3 2008($0.26)($0.27)ViewN/AView Earnings Details
7/22/2008Q2 2008($0.26)($0.20)ViewN/AView Earnings Details
4/24/2008Q1 2008($0.18)($0.22)ViewN/AView Earnings Details
2/7/2008Q4 2007($0.23)($0.22)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Seattle Genetics (NASDAQ:SGEN) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Seattle Genetics (NASDAQ SGEN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 33.80%
Insider Trading History for Seattle Genetics (NASDAQ:SGEN)
Institutional Ownership by Quarter for Seattle Genetics (NASDAQ:SGEN)

Seattle Genetics (NASDAQ SGEN) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/12/2018Darren S ClineEVPSell12,054$69.00$831,726.0072,723View SEC Filing  
6/8/2018Clay B. SiegallInsiderSell18,832$65.12$1,226,339.84View SEC Filing  
5/31/2018Vaughn B. HimesInsiderSell5,000$58.47$292,350.00View SEC Filing  
5/9/2018Clay B. SiegallCEOSell18,832$54.97$1,035,195.04View SEC Filing  
5/9/2018Darren S. ClineEVPSell9,000$55.33$497,970.00View SEC Filing  
5/8/2018Bros. Advisors Lp BakerDirectorBuy460,651$53.34$24,571,124.34View SEC Filing  
5/4/2018Bros. Advisors Lp BakerDirectorBuy204,537$52.68$10,775,009.16View SEC Filing  
5/3/2018Darren S. ClineEVPSell4,000$53.81$215,240.00View SEC Filing  
5/1/2018Bros. Advisors Lp BakerDirectorBuy306,917$51.36$15,763,257.12View SEC Filing  
4/9/2018Clay B. SiegallInsiderSell18,832$50.52$951,392.64View SEC Filing  
3/15/2018Vaughn B. HimesInsiderSell5,000$58.12$290,600.00View SEC Filing  
3/9/2018Clay B. SiegallCEOSell18,832$57.32$1,079,450.24View SEC Filing  
3/5/2018Jonathan G. DrachmanCMOSell10,457$52.83$552,443.31View SEC Filing  
2/9/2018Clay B. SiegallInsiderSell18,832$49.75$936,892.00View SEC Filing  
2/1/2018Bros. Advisors Lp BakerDirectorBuy3,846,153$52.00$199,999,956.00View SEC Filing  
1/11/2018Clay B. SiegallInsiderSell18,832$51.71$973,802.72View SEC Filing  
12/11/2017Clay B. SiegallInsiderSell18,832$55.40$1,043,292.80View SEC Filing  
12/4/2017Eric DobmeierCOOSell3,729$58.75$219,078.75View SEC Filing  
11/30/2017Vaughn B. HimesInsiderSell10,000$59.97$599,700.00View SEC Filing  
11/17/2017Eric DobmeierCOOSell35,000$58.25$2,038,750.00View SEC Filing  
11/15/2017Eric DobmeierCOOSell9,600$57.80$554,880.00View SEC Filing  
11/15/2017Marc E. LippmanDirectorSell3,000$58.07$174,210.00View SEC Filing  
11/10/2017Clay B. SiegallInsiderSell18,832$58.00$1,092,256.00View SEC Filing  
11/1/2017Todd E. SimpsonCFOSell39,385$60.91$2,398,940.35View SEC Filing  
10/11/2017Clay B SiegallInsiderSell18,832$61.18$1,152,141.76View SEC Filing  
9/11/2017Clay B. SiegallInsiderSell18,832$53.49$1,007,323.68View SEC Filing  
9/8/2017Vaughn B. HimesInsiderSell10,000$53.22$532,200.00View SEC Filing  
9/6/2017Darren S. ClineEVPSell5,024$51.94$260,946.56View SEC Filing  
9/6/2017Todd E. SimpsonCFOSell9,638$52.00$501,176.00View SEC Filing  
8/31/2017Darren S. ClineEVPSell7,569$52.51$397,448.19View SEC Filing  
8/31/2017Eric DobmeierCOOSell25,000$52.24$1,306,000.00View SEC Filing  
8/28/2017Clay B. SiegallCEOSell25,506$47.89$1,221,482.34View SEC Filing  
8/28/2017Darren S. ClineEVPSell1,788$47.89$85,627.32View SEC Filing  
8/28/2017Eric DobmeierCOOSell5,343$47.89$255,876.27View SEC Filing  
8/28/2017Jonathan G. DrachmanCMOSell8,502$47.89$407,160.78View SEC Filing  
8/28/2017Todd E. SimpsonCFOSell4,937$47.89$236,432.93View SEC Filing  
8/28/2017Vaughn B. HimesInsiderSell6,377$47.89$305,394.53View SEC Filing  
8/24/2017Jonathan G. DrachmanCMOSell10,000$47.54$475,400.00View SEC Filing  
8/7/2017Clay B. SiegallInsiderSell10,413$48.91$509,299.83View SEC Filing  
8/7/2017Darren S. ClineEVPSell6,000$49.19$295,140.00View SEC Filing  
7/27/2017Jonathan G. DrachmanCMOSell10,000$54.54$545,400.00View SEC Filing  
7/5/2017Clay B. SiegallCEOSell10,423$51.98$541,787.54View SEC Filing  
6/22/2017Jonathan G DrachmanCMOSell10,000$64.01$640,100.00125,204View SEC Filing  
6/5/2017Clay B. SiegallInsiderSell10,423$65.21$679,683.83View SEC Filing  
4/5/2017Clay B SiegallInsiderSell14,465$62.99$911,150.35646,858View SEC Filing  
3/31/2017Vaughn B HimesInsiderSell10,000$62.75$627,500.00161,283View SEC Filing  
3/6/2017Clay B SiegallCEOSell14,465$68.04$984,198.60646,858View SEC Filing  
2/6/2017Clay B SiegallInsiderSell14,465$61.54$890,176.10640,477View SEC Filing  
1/6/2017Clay B. SiegallInsiderSell14,465$57.89$837,378.85View SEC Filing  
12/13/2016Darren S. ClineEVPSell10,000$63.38$633,800.00View SEC Filing  
12/8/2016Eric DobmeierCOOSell12,500$65.92$824,000.00View SEC Filing  
12/7/2016Vaughn B. HimesInsiderSell30,000$65.32$1,959,600.00View SEC Filing  
11/8/2016Felix BakerDirectorBuy382,500$59.36$22,705,200.00View SEC Filing  
11/7/2016Clay B. SiegallCEOSell14,465$58.43$845,189.95View SEC Filing  
11/7/2016Marc E. LippmanDirectorSell1,000$57.75$57,750.00View SEC Filing  
11/3/2016Felix BakerDirectorBuy1,030,629$56.13$57,849,205.77View SEC Filing  
11/1/2016Jonathan G. DrachmanCMOSell3,418$51.74$176,847.32View SEC Filing  
10/6/2016Clay B. SiegallInsiderSell14,465$54.41$787,040.65View SEC Filing  
9/22/2016Jonathan G DrachmanCMOSell2,249$56.75$127,630.75115,504View SEC Filing  
9/14/2016Eric DobmeierCOOSell22,918$54.04$1,238,488.72View SEC Filing  
9/13/2016Felix BakerDirectorBuy447,311$50.71$22,683,140.81View SEC Filing  
9/8/2016Clay B. SiegallInsiderSell31,269$50.08$1,565,951.52View SEC Filing  
9/8/2016Felix BakerDirectorBuy414,016$48.43$20,050,794.88View SEC Filing  
8/23/2016Eric DobmeierCOOSell12,589$48.00$604,272.00View SEC Filing  
8/22/2016Clay B. SiegallInsiderSell23,381$46.59$1,089,320.79View SEC Filing  
8/22/2016Eric DobmeierCOOSell5,411$46.59$252,098.49View SEC Filing  
8/22/2016Vaughn B. HimesEVPSell3,991$46.59$185,940.69View SEC Filing  
8/8/2016Clay B. SiegallInsiderSell11,660$47.19$550,235.40View SEC Filing  
7/27/2016Clay B. SiegallInsiderSell4,042$45.20$182,698.40View SEC Filing  
7/6/2016Clay B. SiegallCEOSell7,618$40.56$308,986.08View SEC Filing  
6/6/2016Clay B SiegallCEOSell22,083$43.59$962,597.97566,538View SEC Filing  
6/2/2016Darren S ClineEVPSell3,366$42.07$141,607.6242,747View SEC Filing  
5/27/2016Clay B SiegallCEOSell48,660$40.41$1,966,350.60563,883View SEC Filing  
5/24/2016Clay B SiegallCEOSell8,400$40.09$336,756.00562,815View SEC Filing  
5/23/2016Clay B SiegallCEOSell6,700$40.12$268,804.00562,815View SEC Filing  
5/17/2016Clay B SiegallCEOSell7,618$35.16$267,848.88563,733View SEC Filing  
4/25/2016Clay B SiegallCEOSell800$40.00$32,000.00556,915View SEC Filing  
4/5/2016Clay B SiegallCEOSell7,618$36.12$275,162.16563,733View SEC Filing  
3/22/2016Clay B SiegallCEOSell15,236$35.52$541,182.72560,397View SEC Filing  
3/21/2016Clay B SiegallCEOSell4,282$35.01$149,912.82560,397View SEC Filing  
3/17/2016Felix BakerDirectorBuy124,065$31.85$3,951,470.2538,783,387View SEC Filing  
3/16/2016Felix BakerDirectorBuy1,349,237$32.10$43,310,507.70107,511View SEC Filing  
3/15/2016Felix BakerDirectorBuy661,093$32.08$21,207,863.4438,671,506View SEC Filing  
3/14/2016Felix BakerDirectorBuy118,941$33.77$4,016,637.5738,671,506View SEC Filing  
3/11/2016Felix BakerDirectorBuy694,666$32.46$22,548,858.3637,454,776View SEC Filing  
3/8/2016Felix BakerDirectorBuy502,523$22.66$11,387,171.18107,511View SEC Filing  
3/2/2016Felix BakerDirectorBuy675,922$31.77$21,474,041.94107,511View SEC Filing  
3/1/2016Felix BakerDirectorBuy24,200$31.24$756,008.00107,511View SEC Filing  
2/29/2016Felix BakerDirectorBuy251,722$30.39$7,649,831.58107,511View SEC Filing  
2/26/2016Felix BakerDirectorBuy314,508$29.55$9,293,711.40View SEC Filing  
2/22/2016Felix BakerDirectorBuy1,001,471$29.63$29,673,585.73View SEC Filing  
2/17/2016Felix BakerDirectorBuy1,269,147$30.43$38,620,143.21View SEC Filing  
2/12/2016John A. OrwinDirectorBuy2,000$28.33$56,660.00View SEC Filing  
12/15/2015Vaughn B. HimesEVPSell40,500$39.94$1,617,570.0076,212View SEC Filing  
12/3/2015Clay B. SiegallCEOSell3,720$39.99$148,762.80556,115View SEC Filing  
11/20/2015Felix BakerDirectorBuy329,358$43.94$14,471,990.52107,504View SEC Filing  
11/17/2015Clay B SiegallCEOSell87,473$45.40$3,971,274.20556,115View SEC Filing  
11/11/2015Darren S ClineSVPSell5,769$45.68$263,527.9237,713View SEC Filing  
11/10/2015Felix BakerDirectorBuy934,624$42.95$40,142,100.80107,504View SEC Filing  
11/9/2015Felix BakerDirectorBuy507,300$43.76$22,199,448.00107,504View SEC Filing  
11/6/2015Eric DobmeierCOOSell17,452$42.50$741,710.0080,888View SEC Filing  
11/6/2015Felix BakerDirectorBuy417,924$41.94$17,527,732.56107,504View SEC Filing  
11/5/2015David W GryskaDirectorSell10,000$43.57$435,700.0023,950View SEC Filing  
11/4/2015Clay B. SiegallCEOSell3,718$43.14$160,394.52643,588View SEC Filing  
10/5/2015Clay B. SiegallCEOSell3,718$41.30$153,553.40611,323View SEC Filing  
9/3/2015Clay B. SiegallCEOSell3,718$40.12$149,166.16611,323View SEC Filing  
8/20/2015Clay B. SiegallCEOSell31,754$42.02$1,334,303.08611,323View SEC Filing  
8/20/2015Darren S. ClineSVPSell2,231$42.02$93,746.6243,482View SEC Filing  
8/20/2015Eric DobmeierCOOSell8,548$42.02$359,186.9698,340View SEC Filing  
8/20/2015Jonathan G. DrachmanCMOSell4,462$42.02$187,493.2482,724View SEC Filing  
8/20/2015Todd E. SimpsonCFOSell5,825$42.02$244,766.50179,874View SEC Filing  
8/20/2015Vaughn B. HimesEVPSell5,997$42.02$251,993.9476,212View SEC Filing  
7/6/2015Clay B SiegallCEOSell3,718$46.94$174,522.92View SEC Filing  
6/3/2015Clay B SiegallCEOSell3,718$45.72$169,986.96View SEC Filing  
5/21/2015Felix BakerDirectorBuy950,886$42.49$40,403,146.14View SEC Filing  
5/8/2015Eric DobmeierCOOSell17,074$40.38$689,448.12View SEC Filing  
5/7/2015Felix BakerDirectorBuy1,032,664$35.56$36,721,531.84View SEC Filing  
3/10/2015Felix BakerDirectorBuy285,036$34.66$9,879,347.76View SEC Filing  
3/9/2015Felix BakerDirectorBuy275,717$34.66$9,556,351.22View SEC Filing  
3/4/2015Felix BakerDirectorBuy448,841$34.84$15,637,620.44View SEC Filing  
2/25/2015Felix BakerDirectorBuy281,115$33.92$9,535,420.80View SEC Filing  
1/6/2015Clay B SiegallCEOSell16,804$31.80$534,367.20View SEC Filing  
12/16/2014Felix BakerDirectorBuy2,883,378$31.86$91,864,423.08View SEC Filing  
12/10/2014Felix BakerDirectorBuy1,247,896$33.82$42,203,842.72View SEC Filing  
12/9/2014Felix BakerDirectorBuy128,430$34.16$4,387,168.80View SEC Filing  
12/8/2014Felix BakerDirectorBuy465,316$32.93$15,322,855.88View SEC Filing  
11/12/2014Vaughn B HimesEVPSell10,000$37.52$375,200.00View SEC Filing  
11/10/2014Felix BakerDirectorBuy1,653,925$34.56$57,159,648.00View SEC Filing  
9/4/2014Clay B SiegallCEOSell5,600$42.54$238,224.00View SEC Filing  
8/12/2014Clay B SiegallCEOSell11,200$40.38$452,256.00View SEC Filing  
8/11/2014Clay B SiegallCEOSell2,700$40.05$108,135.00View SEC Filing  
6/13/2014Felix BakerDirectorBuy216,595$39.92$8,646,472.40View SEC Filing  
6/10/2014Clay B SiegallCEOSell11,200$40.14$449,568.00View SEC Filing  
6/9/2014Felix BakerDirectorBuy546,252$38.16$20,844,976.32View SEC Filing  
6/4/2014Felix BakerDirectorBuy281,963$34.86$9,829,230.18View SEC Filing  
5/16/2014Felix BakerDirectorBuy189,611$34.07$6,460,046.7776,997View SEC Filing  
4/3/2014Clay SiegallCEOSell5,600$43.34$242,704.00955,696View SEC Filing  
2/18/2014Clay SiegallCEOSell100,000$51.97$5,197,000.00955,696View SEC Filing  
1/21/2014Eric DobmeierCOOSell56,010$47.92$2,683,999.2077,833View SEC Filing  
1/16/2014Jonathan DrachmanCMOSell1,201$45.75$54,945.7549,911View SEC Filing  
12/16/2013Felix BakerDirectorBuy407,078$39.66$16,144,713.4876,997View SEC Filing  
12/5/2013Felix BakerDirectorBuy1,005,901$43.19$43,444,864.1976,997View SEC Filing  
10/1/2013Clay B SiegallCEOSell2,000$43.87$87,740.00View SEC Filing  
9/10/2013Eric DobmeierCOOSell42,000$46.40$1,948,800.00View SEC Filing  
9/5/2013Eric DobmeierCOOSell75,000$42.64$3,198,000.00View SEC Filing  
9/3/2013Clay B SiegallCEOSell102,000$43.90$4,477,800.00View SEC Filing  
9/3/2013David W GryskaDirectorSell10,000$42.48$424,800.00View SEC Filing  
8/27/2013Todd SimpsonCFOSell37,763$41.45$1,565,276.35155,395View SEC Filing  
8/19/2013Clay SiegallCEOSell7,653$40.91$313,084.231,124,558View SEC Filing  
8/19/2013Eric DobmeierCOOSell3,328$40.91$136,148.48127,620View SEC Filing  
8/19/2013Vaughn HimesEVPSell1,736$40.91$71,019.7646,307View SEC Filing  
8/1/2013Clay B SiegallCEOSell2,000$40.03$80,060.00View SEC Filing  
7/12/2013Todd E SimpsonCFOSell92,527$37.45$3,465,136.15View SEC Filing  
7/1/2013Clay B SiegallCEOSell2,000$32.59$65,180.00View SEC Filing  
6/14/2013Srinivas AkkarajuDirectorSell5,000$32.75$163,750.00View SEC Filing  
6/13/2013Vaughn B HimesEVPSell10,000$32.11$321,100.00View SEC Filing  
6/3/2013Clay B SiegallCEOSell2,000$33.88$67,760.00View SEC Filing  
5/10/2013Srinivas AkkarajuDirectorSell17,500$37.17$650,475.00View SEC Filing  
3/6/2013Eric DobmeierCOOSell100,000$29.68$2,968,000.00View SEC Filing  
2/25/2013David W GryskaDirectorSell10,000$27.17$271,700.00View SEC Filing  
2/1/2013Clay B SiegallCEOSell2,000$29.61$59,220.00View SEC Filing  
1/15/2013Thomas C ReynoldsInsiderSell125,079$28.00$3,502,212.00View SEC Filing  
11/1/2012Clay B SiegallCEOSell8,250$25.51$210,457.50View SEC Filing  
9/4/2012Clay B SiegallCEOSell8,250$26.54$218,955.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Seattle Genetics (NASDAQ SGEN) News Headlines

Source:
DateHeadline
Seattle Genetics, Inc. (SGEN) EVP Sells $831,726.00 in StockSeattle Genetics, Inc. (SGEN) EVP Sells $831,726.00 in Stock
www.americanbankingnews.com - June 14 at 10:34 PM
Seattle Genetics (SGEN) Reports First Patient Dosed in Phase 2 Trial of Tisotumab VedotinSeattle Genetics (SGEN) Reports First Patient Dosed in Phase 2 Trial of Tisotumab Vedotin
www.streetinsider.com - June 14 at 5:08 PM
Form 4 SEATTLE GENETICS INC For: Jun 08 Filed by: SIEGALL CLAY BForm 4 SEATTLE GENETICS INC For: Jun 08 Filed by: SIEGALL CLAY B
www.streetinsider.com - June 14 at 5:08 PM
Seattle Genetics Announces First Patient Dosed in Phase 2 Trial of Tisotumab Vedotin for Women with Recurrent or ...Seattle Genetics Announces First Patient Dosed in Phase 2 Trial of Tisotumab Vedotin for Women with Recurrent or ...
www.businesswire.com - June 14 at 5:08 PM
Seattle Genetics, Inc. to Post Q3 2018 Earnings of ($0.35) Per Share, SunTrust Banks Forecasts (SGEN)Seattle Genetics, Inc. to Post Q3 2018 Earnings of ($0.35) Per Share, SunTrust Banks Forecasts (SGEN)
www.americanbankingnews.com - June 14 at 6:26 AM
Seattle Genetics commences mid-stage study of tisotumab vedotin in cervical cancerSeattle Genetics commences mid-stage study of tisotumab vedotin in cervical cancer
seekingalpha.com - June 13 at 5:01 PM
Seattle Genetics Announces First Patient Dosed in Phase 2 Trial of Tisotumab Vedotin for Women with Recurrent or Metastatic Cervical CancerSeattle Genetics Announces First Patient Dosed in Phase 2 Trial of Tisotumab Vedotin for Women with Recurrent or Metastatic Cervical Cancer
finance.yahoo.com - June 13 at 8:44 AM
Insider Selling: Seattle Genetics, Inc. (SGEN) Insider Sells 18,832 Shares of StockInsider Selling: Seattle Genetics, Inc. (SGEN) Insider Sells 18,832 Shares of Stock
www.americanbankingnews.com - June 12 at 10:28 PM
Seattle Genetics (SGEN) Lifted to Buy at SunTrust BanksSeattle Genetics (SGEN) Lifted to Buy at SunTrust Banks
www.americanbankingnews.com - June 11 at 11:22 AM
Form 4 SEATTLE GENETICS INC For: May 31 Filed by: HIMES VAUGHN BForm 4 SEATTLE GENETICS INC For: May 31 Filed by: HIMES VAUGHN B
www.streetinsider.com - June 6 at 4:59 PM
Seattle Genetics to Present at the Goldman Sachs 39Seattle Genetics to Present at the Goldman Sachs 39
www.businesswire.com - June 6 at 4:59 PM
Seattle Genetics to Present at the Goldman Sachs 39th Annual Global Healthcare ConferenceSeattle Genetics to Present at the Goldman Sachs 39th Annual Global Healthcare Conference
finance.yahoo.com - June 6 at 8:55 AM
Seattle Genetics Sees Unusually High Options Volume (SGEN)Seattle Genetics Sees Unusually High Options Volume (SGEN)
www.americanbankingnews.com - June 6 at 7:30 AM
HC Wainwright Reiterates "Buy" Rating for Seattle Genetics (SGEN)HC Wainwright Reiterates "Buy" Rating for Seattle Genetics (SGEN)
www.americanbankingnews.com - June 5 at 1:35 PM
Seattle Genetics, Inc. (SGEN) Expected to Announce Quarterly Sales of $139.99 MillionSeattle Genetics, Inc. (SGEN) Expected to Announce Quarterly Sales of $139.99 Million
www.americanbankingnews.com - June 5 at 3:36 AM
Insider Selling: Seattle Genetics, Inc. (SGEN) Insider Sells 5,000 Shares of StockInsider Selling: Seattle Genetics, Inc. (SGEN) Insider Sells 5,000 Shares of Stock
www.americanbankingnews.com - June 4 at 10:14 PM
Seattle Genetics and Astellas Present at ASCO 2018 on Enfortumab Vedotin in Patients with Locally Advanced or ...Seattle Genetics and Astellas Present at ASCO 2018 on Enfortumab Vedotin in Patients with Locally Advanced or ...
www.businesswire.com - June 4 at 4:49 PM
Seattle Genetics (SGEN) & Astellas Update Phase 1 Data of Investigational Antibody-Drug Conjugate Enfortumab ...Seattle Genetics (SGEN) & Astellas Update Phase 1 Data of Investigational Antibody-Drug Conjugate Enfortumab ...
www.streetinsider.com - June 4 at 4:49 PM
Astellas and Seattle Genetics Present at ASCO 2018 on Enfortumab Vedotin in Patients with Locally Advanced or ...Astellas and Seattle Genetics Present at ASCO 2018 on Enfortumab Vedotin in Patients with Locally Advanced or ...
www.prnewswire.com - June 4 at 4:49 PM
Seattle Genetics Highlights Additional Analyses from Phase 3 ECHELON-1 Clinical Trial of ADCETRISSeattle Genetics Highlights Additional Analyses from Phase 3 ECHELON-1 Clinical Trial of ADCETRIS
www.businesswire.com - June 4 at 4:49 PM
Seattle Genetics Highlights Additional Analyses from Phase 3 ECHELON-1 Clinical Trial of ADCETRIS® (Brentuximab Vedotin) in Newly Diagnosed Advanced Hodgkin Lymphoma at 2018 ASCO Annual MeetingSeattle Genetics Highlights Additional Analyses from Phase 3 ECHELON-1 Clinical Trial of ADCETRIS® (Brentuximab Vedotin) in Newly Diagnosed Advanced Hodgkin Lymphoma at 2018 ASCO Annual Meeting
finance.yahoo.com - June 4 at 4:49 PM
Seattle Genetics, Inc. (SGEN) Receives Average Recommendation of "Hold" from AnalystsSeattle Genetics, Inc. (SGEN) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - June 4 at 3:25 AM
 Analysts Anticipate Seattle Genetics, Inc. (SGEN) Will Post Earnings of -$0.34 Per Share Analysts Anticipate Seattle Genetics, Inc. (SGEN) Will Post Earnings of -$0.34 Per Share
www.americanbankingnews.com - June 3 at 9:52 AM
3 Biotech Stocks Poised for 12% Gains3 Biotech Stocks Poised for 12% Gains
finance.yahoo.com - June 1 at 5:07 PM
Todays Research Reports on Trending Tickers: Arena Pharmaceuticals and Seattle GeneticsToday's Research Reports on Trending Tickers: Arena Pharmaceuticals and Seattle Genetics
finance.yahoo.com - June 1 at 8:57 AM
Head to Head Analysis: Amgen (AMGN) & Seattle Genetics (SGEN)Head to Head Analysis: Amgen (AMGN) & Seattle Genetics (SGEN)
www.americanbankingnews.com - June 1 at 1:06 AM
Incyte’s Collaborations and Developments in Q1 2018Incyte’s Collaborations and Developments in Q1 2018
finance.yahoo.com - May 30 at 4:55 PM
Why Is Seattle Genetics (SGEN) Up 13.3% Since Its Last Earnings Report?Why Is Seattle Genetics (SGEN) Up 13.3% Since Its Last Earnings Report?
finance.yahoo.com - May 28 at 9:01 AM
An Ear To The Pharma: 12 Stocks To Watch (AIMT, TXMD, MDGL…)An Ear To The Pharma: 12 Stocks To Watch (AIMT, TXMD, MDGL…)
www.nasdaq.com - May 27 at 9:15 AM
Oppenheimer Weighs in on Seattle Genetics FY2022 Earnings (SGEN)Oppenheimer Weighs in on Seattle Genetics' FY2022 Earnings (SGEN)
www.americanbankingnews.com - May 21 at 2:00 AM
Zacks: Analysts Anticipate Seattle Genetics (SGEN) Will Post Quarterly Sales of $139.99 MillionZacks: Analysts Anticipate Seattle Genetics (SGEN) Will Post Quarterly Sales of $139.99 Million
www.americanbankingnews.com - May 19 at 4:22 AM
Seattle Genetics Appoints Roger D. Dansey, M.D., Chief Medical OfficerSeattle Genetics Appoints Roger D. Dansey, M.D., Chief Medical Officer
finance.yahoo.com - May 17 at 5:34 PM
Seattle Genetics (SGEN) Receives Hold Rating from CannSeattle Genetics (SGEN) Receives Hold Rating from Cann
www.americanbankingnews.com - May 17 at 4:17 PM
Seattle Genetics Announces Data Presentations at 2018 ASCO Annual MeetingSeattle Genetics Announces Data Presentations at 2018 ASCO Annual Meeting
finance.yahoo.com - May 17 at 8:59 AM
 Brokerages Anticipate Seattle Genetics (SGEN) Will Post Earnings of -$0.36 Per Share Brokerages Anticipate Seattle Genetics (SGEN) Will Post Earnings of -$0.36 Per Share
www.americanbankingnews.com - May 17 at 5:15 AM
Seattle Genetics (SGEN) Upgraded to Hold at BidaskClubSeattle Genetics (SGEN) Upgraded to Hold at BidaskClub
www.americanbankingnews.com - May 16 at 10:30 AM
Acorda Therapeutics (ACOR) versus Seattle Genetics (SGEN) Critical ComparisonAcorda Therapeutics (ACOR) versus Seattle Genetics (SGEN) Critical Comparison
www.americanbankingnews.com - May 15 at 10:46 AM
Seattle Genetics Fairly Valued, Pending DataSeattle Genetics Fairly Valued, Pending Data
seekingalpha.com - May 14 at 4:59 PM
Seattle Genetics (SGEN) CEO Sells $1,035,195.04 in StockSeattle Genetics (SGEN) CEO Sells $1,035,195.04 in Stock
www.americanbankingnews.com - May 11 at 10:38 PM
Darren S. Cline Sells 9,000 Shares of Seattle Genetics (SGEN) StockDarren S. Cline Sells 9,000 Shares of Seattle Genetics (SGEN) Stock
www.americanbankingnews.com - May 11 at 10:35 PM
Alpine: Elucidating The Acquisition Prospects Of A Young Sleeping GiantAlpine: Elucidating The Acquisition Prospects Of A Young Sleeping Giant
seekingalpha.com - May 11 at 5:14 PM
Seattle Genetics (SGEN) Receives Consensus Recommendation of "Hold" from AnalystsSeattle Genetics (SGEN) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - May 10 at 3:32 AM
Insider Buying: Seattle Genetics (SGEN) Director Buys 204,537 Shares of StockInsider Buying: Seattle Genetics (SGEN) Director Buys 204,537 Shares of Stock
www.americanbankingnews.com - May 8 at 7:22 PM
Seattle Genetics (SGEN) Director Bros. Advisors Lp Baker Buys 460,651 SharesSeattle Genetics (SGEN) Director Bros. Advisors Lp Baker Buys 460,651 Shares
www.americanbankingnews.com - May 8 at 7:22 PM
Seattle Genetics (SGEN) EVP Darren S. Cline Sells 4,000 SharesSeattle Genetics (SGEN) EVP Darren S. Cline Sells 4,000 Shares
www.americanbankingnews.com - May 7 at 10:26 PM
Blog Exposure - Cellectar Receives Rare Pediatric Disease Designation from FDABlog Exposure - Cellectar Receives Rare Pediatric Disease Designation from FDA
finance.yahoo.com - May 4 at 8:48 AM
The Bothell economy: City looks to Lake Union area as model to build up biotech hubThe Bothell economy: City looks to Lake Union area as model to build up biotech hub
finance.yahoo.com - May 3 at 4:57 PM
Investors Buy High Volume of Seattle Genetics Call Options (SGEN)Investors Buy High Volume of Seattle Genetics Call Options (SGEN)
www.americanbankingnews.com - May 3 at 8:21 AM
Seattle Genetics (SGEN) Director Purchases $15,763,257.12 in StockSeattle Genetics (SGEN) Director Purchases $15,763,257.12 in Stock
www.americanbankingnews.com - May 2 at 7:22 PM
BidaskClub Upgrades Seattle Genetics (SGEN) to "Sell"BidaskClub Upgrades Seattle Genetics (SGEN) to "Sell"
www.americanbankingnews.com - May 2 at 1:04 PM

SEC Filings

Seattle Genetics (NASDAQ:SGEN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Seattle Genetics (NASDAQ:SGEN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Seattle Genetics (NASDAQ SGEN) Stock Chart for Sunday, June, 17, 2018

Loading chart…

This page was last updated on 6/17/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.